Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 9:9:3306.
doi: 10.3389/fmicb.2018.03306. eCollection 2018.

Perspectives of Phage Therapy in Non-bacterial Infections

Andrzej Górski  1   2 , Paul L Bollyky  3   4 , Maciej Przybylski  5 , Jan Borysowski  2 , Ryszard Międzybrodzki  1   2 , Ewa Jończyk-Matysiak  1 , Beata Weber-Dąbrowska  1
Affiliations

Perspectives of Phage Therapy in Non-bacterial Infections

Andrzej Górski et al. Front Microbiol. .

Abstract

While the true value of phage therapy (PT) in human bacterial infections still awaits formal confirmation by clinical trials, new data have been accumulating indicating that in the future PT may be applied in the treatment of non-bacterial infections. Thus, "phage guests" may interact with eukaryotic cells and such interactions with cells of the immune system may protect human health (Guglielmi, 2017) and cause clinically useful immunomodulatory and anti-inflammatory effects when administered for therapeutic purposes (Górski et al., 2017; Van Belleghem et al., 2017). Recently, a vision of how these effects could translate into advances in novel means of therapy in a variety of human pathologies secondary to immune disturbances and allergy was presented (Górski et al., 2018a). In this article we present what is currently known about anti-microbial effects of phage which are not directly related to their antibacterial action and how these findings could be applied in the future in treatment of viral and fungal infections.

Keywords: drug repurposing; fungal infection; phage; phage therapy; viral infection.

PubMed Disclaimer

References

    1. Amin R., Dupuis A., Aaron S. D., Ratjen F. (2010). The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 137 171–176. 10.1378/chest.09-1103 - DOI - PubMed
    1. Anand R., Moss R. B., Sass G., Banaei N., Clemons K. V., Martinez M., et al. (2018). Small colony variants of Pseudomonas aeruginosa display heterogeneity in inhibiting Aspergillus fumigatus biofilm. Mycopathologia 183 263–272. 10.1007/s11046-017-0186-9 - DOI - PubMed
    1. Baxter C. G., Rautemaa R., Jones A. M., Webb A. K., Bull M., Mahenthiralingam E., et al. (2013). Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum. Thorax 68 652–657. 10.1136/thoraxjnl-2012-202412 - DOI - PubMed
    1. Bjarnsholt T., Jensen P. Ø., Fiandaca M. J., Pedersen J., Hansen C. R., Andersen C. B. et al. (2009). Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr. Pulmonol. 44 547–558. 10.1002/ppul.21011 - DOI - PubMed
    1. Blyth W. (1971). Modifications in the ultrastructure of Aspergillus fumigatus due to the presence of living cells of Pseudomonas aeruginosa. Sabouraudia 9 283–286. 10.1080/00362177185190541 - DOI - PubMed

LinkOut - more resources